CY1116894T1 - Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων - Google Patents

Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων

Info

Publication number
CY1116894T1
CY1116894T1 CY20151100997T CY151100997T CY1116894T1 CY 1116894 T1 CY1116894 T1 CY 1116894T1 CY 20151100997 T CY20151100997 T CY 20151100997T CY 151100997 T CY151100997 T CY 151100997T CY 1116894 T1 CY1116894 T1 CY 1116894T1
Authority
CY
Cyprus
Prior art keywords
pal
compositions
methods
fenylalanine
lysis
Prior art date
Application number
CY20151100997T
Other languages
Greek (el)
English (en)
Inventor
Michel C Vellard
Paul A Fitzpatrick
Emil D Kakkis
Daniel J Wendt
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39868905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116894(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of CY1116894T1 publication Critical patent/CY1116894T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20151100997T 2007-05-25 2015-11-06 Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων CY1116894T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/807,227 US7534595B2 (en) 2006-06-12 2007-05-25 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
EP08754717.0A EP2152868B1 (en) 2007-05-25 2008-05-23 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions

Publications (1)

Publication Number Publication Date
CY1116894T1 true CY1116894T1 (el) 2017-04-05

Family

ID=39868905

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100997T CY1116894T1 (el) 2007-05-25 2015-11-06 Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων
CY2019039C CY2019039I2 (el) 2007-05-25 2019-10-17 Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2019039C CY2019039I2 (el) 2007-05-25 2019-10-17 Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων

Country Status (29)

Country Link
US (1) US7534595B2 (https=)
EP (2) EP2152868B1 (https=)
JP (1) JP5670183B2 (https=)
KR (2) KR20150038753A (https=)
CN (1) CN101842482B (https=)
AR (2) AR066716A1 (https=)
AU (1) AU2008263190B2 (https=)
BR (1) BRPI0811267B8 (https=)
CA (1) CA2687450C (https=)
CL (1) CL2008001497A1 (https=)
CY (2) CY1116894T1 (https=)
DK (1) DK2152868T3 (https=)
EA (1) EA018443B1 (https=)
ES (1) ES2551315T3 (https=)
HR (1) HRP20151268T1 (https=)
HU (2) HUE025784T2 (https=)
IL (1) IL202132A (https=)
LT (1) LTC2152868I2 (https=)
LU (1) LUC00133I2 (https=)
MX (1) MX2009012453A (https=)
MY (1) MY151413A (https=)
NL (1) NL301011I2 (https=)
NO (1) NO2019037I1 (https=)
PE (1) PE20090315A1 (https=)
PL (1) PL2152868T3 (https=)
PT (1) PT2152868E (https=)
SI (1) SI2152868T1 (https=)
TW (1) TWI418633B (https=)
WO (1) WO2008153776A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
ES2582459T3 (es) 2010-02-04 2016-09-13 Biomarin Pharmaceutical Inc. Composiciones de variantes de fenilalanina amoníaco-liasa de procariotas y métodos de uso de sus composiciones
CA2880620A1 (en) * 2012-07-27 2014-01-30 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
KR102218930B1 (ko) 2013-04-18 2021-02-23 코덱시스, 인코포레이티드 조작된 페닐알라닌 암모니아 리아제 폴리펩티드
AU2014348683B2 (en) 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
ES2865825T3 (es) 2014-04-01 2021-10-18 Rubius Therapeutics Inc Procedimientos y composiciones para inmunomodulación
WO2015161019A1 (en) 2014-04-16 2015-10-22 Codexis, Inc. Engineered tyrosine ammonia lyase
FI3237621T3 (fi) 2014-12-22 2023-06-01 Codexis Inc Ihmisen alfa-galaktosidaasivariantteja
TW202440904A (zh) * 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法(二)
PE20190401A1 (es) 2016-07-26 2019-03-13 Biomarin Pharm Inc Novedosas proteinas de la capside del virus adenoasociado
CN109844127B (zh) 2016-08-30 2023-09-19 三菱化学株式会社 突变型酶的制造方法及突变型醇酰基转移酶
CN106497905A (zh) * 2016-12-14 2017-03-15 江南大学 一株鱼腥藻来源的苯丙氨酸脱氨酶的突变体
AU2018217495B2 (en) * 2017-02-13 2021-03-04 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
CN107653275A (zh) * 2017-10-30 2018-02-02 安徽工程大学 D‑苯丙氨酸的制备方法
CN108004225B (zh) * 2017-12-19 2020-05-08 江南大学 一种成团泛菌来源的苯丙氨酸氨基变位酶的突变体
BR112020022722A8 (pt) 2018-05-09 2022-01-18 Biomarin Pharm Inc Genoma e seu uso, vetor, partícula, molécula de ácido nucleico isolada, ácido nucleico, composição, tratamento, método
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US10900055B2 (en) * 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
JP2021531749A (ja) * 2018-07-12 2021-11-25 コデクシス, インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
SG11202105668PA (en) 2018-12-14 2021-06-29 Codexis Inc Engineered tyrosine ammonia lyase
SG11202106348QA (en) 2018-12-20 2021-07-29 Codexis Inc Human alpha-galactosidase variants
CN110456056A (zh) * 2019-07-22 2019-11-15 浙江大学 一种新生儿苯丙酮尿症无创筛查试纸的制备方法
EP4501403A3 (en) 2019-08-30 2025-05-14 Société des Produits Nestlé S.A. Engineered lipase variants
KR20220129547A (ko) 2019-12-20 2022-09-23 코덱시스, 인코포레이티드 조작된 산성 알파-글루코시다제 변이체
WO2021158686A1 (en) 2020-02-04 2021-08-12 Codexis, Inc. Engineered leucine decarboxylases
US20230183712A1 (en) * 2020-02-19 2023-06-15 Trustees Of Tufts College Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
EP4204554A4 (en) 2020-08-28 2024-08-21 Codexis, Inc. MODIFIED PROTEASE VARIANTS
MX2023002421A (es) 2020-08-28 2023-05-18 Codexis Inc Variantes de amilasa modificadas geneticamente.
JP2024519847A (ja) 2021-05-19 2024-05-21 ビオマリン プハルマセウトイカル インコーポレイテッド 原核生物フェニルアラニンアンモニアリアーゼの組成物及び青年対象を治療する方法
TW202313969A (zh) 2021-05-21 2023-04-01 美商克迪科思股份有限公司 經工程化的甲硫胺酸γ解離酶變異體
WO2023044381A1 (en) * 2021-09-16 2023-03-23 Arcturus Therapeutics, Inc. Compositions and methods for treating phenylketonuria
CN118475692A (zh) 2021-11-01 2024-08-09 森蒂斯生物公司 工程化亮氨酸脱羧酶
CN117417925A (zh) * 2022-07-18 2024-01-19 浙江泽科塔生物医药有限公司 Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
CN116478975B (zh) * 2023-06-16 2023-09-01 苏州优信合生技术有限公司 高活性苯丙氨酸解氨酶突变体及其表达菌株
WO2025106759A1 (en) 2023-11-17 2025-05-22 Biomarin Pharmaceutical Inc. Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5690929A (en) 1992-11-19 1997-11-25 Anticancer, Inc. Use of methioninase and chemotherapy agents in chemotherapy
DE69233695T2 (de) 1992-12-04 2008-01-24 Me Medical Enzymes Ag Gentechnologisch hergestellte glutaminase und ihre verwendung in therapie
DK75593D0 (https=) 1993-06-25 1993-06-25 Novo Nordisk As
EP0776218A2 (en) * 1994-03-15 1997-06-04 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
CA2230492C (en) 1995-09-21 2009-05-26 Genentech, Inc. Human growth hormone variants
CU22585A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US7026446B1 (en) * 1997-12-24 2006-04-11 Diatech Pty Ltd. Bifunctional molecules
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
IL138990A0 (en) 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
EP1237567B1 (en) * 1999-12-09 2005-08-03 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001257032A1 (en) 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
JP2004523205A (ja) * 2000-07-25 2004-08-05 イムノメディクス, インコーポレイテッド 多価標的結合タンパク質
AU2001294774A1 (en) * 2000-09-26 2002-04-08 The Regents Of The University Of California Characterization of phenylalanine ammonia-lyase (pal) gene in wounded lettuce
EP2343317A1 (en) * 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
EP1476563B1 (en) 2002-02-26 2008-09-17 E.I. Du Pont De Nemours And Company Method for the recombination of genetic elements
EP2351770A1 (en) * 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
US20080124275A1 (en) 2002-11-14 2008-05-29 The Scripps Research Institute Crystalline Form of Fatty Acid Amide Hydrolase (Faah)
EP1636266A2 (en) * 2003-06-11 2006-03-22 Wyeth a Corporation of the State of Delaware Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7553653B2 (en) 2004-09-17 2009-06-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US20090011400A1 (en) 2006-12-01 2009-01-08 The Salk Institute for Biological Studies and The Regents of the University of California Substrate switched ammonia lyases and mutases
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Also Published As

Publication number Publication date
EA018443B1 (ru) 2013-08-30
HUE025784T2 (en) 2016-05-30
KR20150038753A (ko) 2015-04-08
MX2009012453A (es) 2010-01-25
US20080008695A1 (en) 2008-01-10
BRPI0811267A2 (pt) 2014-10-07
LUC00133I2 (https=) 2020-07-16
HRP20151268T1 (hr) 2015-12-18
DK2152868T3 (en) 2015-11-16
PE20090315A1 (es) 2009-03-19
CN101842482A (zh) 2010-09-22
LUC00133I1 (https=) 2019-10-16
EP2152868A1 (en) 2010-02-17
PT2152868E (pt) 2015-11-13
JP5670183B2 (ja) 2015-02-18
LTC2152868I2 (lt) 2020-09-25
EP2152868B1 (en) 2015-09-02
TW200902052A (en) 2009-01-16
CY2019039I1 (el) 2020-05-29
HUS1900049I1 (hu) 2019-11-28
HK1135141A1 (zh) 2010-05-28
NO2019037I1 (no) 2019-10-16
AR110834A2 (es) 2019-05-08
JP2010529835A (ja) 2010-09-02
KR20100024437A (ko) 2010-03-05
KR101603796B1 (ko) 2016-03-17
CY2019039I2 (el) 2020-05-29
TWI418633B (zh) 2013-12-11
CA2687450A1 (en) 2008-12-18
PL2152868T3 (pl) 2016-01-29
EP2657335A1 (en) 2013-10-30
CL2008001497A1 (es) 2009-01-09
IL202132A (en) 2017-06-29
BRPI0811267B1 (pt) 2020-11-10
LTPA2019517I1 (lt) 2019-10-25
AU2008263190B2 (en) 2014-04-17
IL202132A0 (en) 2010-06-16
ES2551315T3 (es) 2015-11-18
WO2008153776A8 (en) 2009-07-30
NL301011I2 (nl) 2020-05-13
SI2152868T1 (sl) 2015-12-31
MY151413A (en) 2014-05-30
CN101842482B (zh) 2014-10-22
US7534595B2 (en) 2009-05-19
NL301011I1 (nl) 2019-10-16
WO2008153776A1 (en) 2008-12-18
AR066716A1 (es) 2009-09-09
CA2687450C (en) 2019-03-26
AU2008263190A1 (en) 2008-12-18
EA200970980A1 (ru) 2010-04-30
BRPI0811267B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CY1116894T1 (el) Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων
CY1118222T1 (el) Συνθεσεις λυασης φαινυλαλανινης αμμωνιας προκαρυωτικων και μεθοδοι αγωγης καρκινου χρησιμοποιωντας συνθεσεις εξ' αυτης
DK2046820T3 (da) Muteiner af tåre-lipocalin og fremgangsmåder til opnåelse deraf
WO2011097335A3 (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
EA201490132A1 (ru) Противовирусные соединения
CY1118048T1 (el) Αντι-ιικες ενωσεις
MX343042B (es) Compuestos heteroarilicos biciclicos.
MX2010009646A (es) Agentes terapeuticos antivirales.
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
TW200722079A (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
EA201171481A1 (ru) Способ получения высококонцентрированного препарата иммуноглобулина для подкожного применения
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA200971074A1 (ru) Антивирусные соединения
EA201001639A1 (ru) Композиции и способы их получения и применения
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
MX2010007587A (es) Compuestos que comprenden un grupo ciclobutoxi.
TW200738741A (en) Antiviral compounds
NZ706052A (en) Romidepsin solid forms and uses thereof
CY1114883T1 (el) Καινοφανεις αντιβακτηριακοι παραγοντες για την αγωγη των κατα gram θετικων λοιμωξεων
EA201071367A1 (ru) Соли соединений ингибиторов вич
TW200716568A (en) 1H-quinazoline-2,4-diones
MX2009000768A (es) Lactamas macrociclicas.
TW200640886A (en) Crystalline forms of linezolid intermediate
EA200800570A1 (ru) Фосфонированные рифамицины и их применение для профилактики и лечения костных и суставных инфекций
HU0402466D0 (en) Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main, intermediates of the process